[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 81
Citations 0
Correction
February 2018

Incorrect Conflicts of Interest Disclosures

JAMA Neurol. 2018;75(2):260. doi:10.1001/jamaneurol.2017.4984

In the Original Investigation titled “Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial,”1 published online December 18, 2017, there were errors in the Conflict of Interest Disclosures. The first sentence for Dr Dodick should have read “Dr Dodick has received compensation from serving on advisory boards and/or consulting….” instead of “Dr Dodick has served, without compensation, on advisory boards and/or has consulted….” Also, entities with which Dr Dodick is associated via advisory boards and consulting agreements were missing from the list and have been added. This article has been corrected online.

References
1.
Skljarevski  V, Oakes  TM, Zhang  Q,  et al.  Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial  [published online December 18, 2017].  JAMA Neurol. doi:10.1001/jamaneurol.2017.3859Google Scholar
×